A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet

Inclusion Criteria: * Body Mass Index \>= 27 and \< 50 * Diagnosis of Type 2 diabetes according to either Swedish guideline or the American Diabetes Association (ADA) criteria * HbA1c \<10.5% at enrollment * No previous oral antidiabetic medication or insulin therapy * Stable body weight * Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing an acceptable method of contraception (requires negative pregnancy test) Exclusion Criteria: * Known contraindication or hypersensitivity to topiramate * Fasting plasma glucose (FPG) \>= 13.1 millimolesl/liter (240 milligrams/deciliter) at baseline, Visit 4 (Week 0) * HBA1c of \>10.5% at enrollment * History of severe recurrent hypoglycemic episodes prior to study entry * Use of any systemic corticosteroids within 30 days of enrollment * Diagnosed Type 1 diabetes * History of significant cardiovascular disease, uncontrolled thyroid disease, or kidney stones